What is the prevalence of Smith-Lemli-Opitz Syndrome?

Smith-Lemli-Opitz syndrome (SLOS) is a rare genetic disorder characterized by an inability to synthesize cholesterol, with an estimated prevalence ranging from 1 in 20,000 to 1 in 60,000 live births. Due to the high rate of clinical underdiagnosis and the lethality of severe cases, the true incidence of Smith-Lemli-Opitz syndrome remains difficult to establish with absolute certainty.

How common is Smith-Lemli-Opitz syndrome?

Smith-Lemli-Opitz syndrome is classified as a rare, autosomal recessive metabolic condition. While prevalence estimates vary, clinical literature, including data from the NIH Genetic and Rare Diseases Information Center (GARD), suggests that the condition is most frequently diagnosed in populations of European descent, particularly those of Central European origin. In some North American and European populations, the incidence is estimated at approximately 1 in 20,000 to 1 in 60,000. It is important to note that these figures are estimates; because milder forms of Smith-Lemli-Opitz syndrome may present with subtle clinical features, many individuals likely remain undiagnosed throughout their lives.

Are there variations in how Smith-Lemli-Opitz syndrome affects different groups?

Smith-Lemli-Opitz syndrome affects both males and females equally, as the underlying genetic mutation occurs on chromosome 11 (the DHCR7 gene), which is not a sex chromosome. However, the condition is typically identified at birth or in early childhood, making it a pediatric-onset disorder. While the condition is globally distributed, the carrier frequency is notably higher in specific Caucasian populations compared to African or Asian populations. Clinical challenges in establishing accurate prevalence data for Smith-Lemli-Opitz syndrome include:

• High rates of misdiagnosis due to the broad, non-specific spectrum of physical and developmental symptoms.


• Early lethality in severe cases, which may result in under-reporting of prenatal or neonatal deaths.


• Variable expressivity, where individuals with "mild" variants of Smith-Lemli-Opitz syndrome may only present with minor physical anomalies or learning disabilities.

What is the role of the DiseaseMaps community in understanding prevalence?

While clinical databases provide statistical estimates, real-world data offers a vital perspective on the lived experience of rare diseases. Currently, 61 people with Smith-Lemli-Opitz syndrome have joined the DiseaseMaps.org community and shared their experiences. This community data serves as a crucial complement to traditional epidemiological research, helping to connect families, track the progression of Smith-Lemli-Opitz syndrome across different age groups, and provide a support network that clinical statistics alone cannot offer.

Next steps

• Consult a clinical geneticist or a metabolic specialist to discuss diagnostic testing if you suspect a family history of Smith-Lemli-Opitz syndrome.


• Join the DiseaseMaps.org community to connect with other families navigating the challenges of this condition.


• Review your family history with a genetic counselor to determine the risk of recurrence in future pregnancies.


• Stay updated on research through the Smith-Lemli-Opitz Foundation to learn about emerging therapeutic interventions and clinical trial opportunities.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Smith-Lemli-Opitz syndrome overview.


• Orphanet: Prevalence and epidemiology of rare metabolic diseases (ORPHA: 813).


• OMIM (Online Mendelian Inheritance in Man): DHCR7 gene and Smith-Lemli-Opitz syndrome (Entry #270400).


• DiseaseMaps.org: Community insights and patient-reported data for Smith-Lemli-Opitz syndrome.